Therapeutic Targeting of Neuroendocrine Prostate Cancer

Abstract

Neuroendocrine prostate cancer is an advanced form of this disease with very limited option of effective treatment. It has been shown that BRN2 is highly expressed in NEPC, and preliminary in vitro data show that inhibition of BRN2 decreases tumor cells growth. We will perform preclinical evaluation of efficacy of a novel BRN2 inhibitor alone, in combination with carboplatin (a standard therapy for neuroendocrine prostate cancer) to determine whether this treatment inhibits progression of NEPC and provides survival benefits.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2021
Accession Number
AD1149898

Entities

People

  • Amina Zoubeidi
  • Colm Morrissey
  • Eva Corey

Organizations

  • University of Washington

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • British Columbia
  • Cancer
  • Carcinoma
  • Carrier Proteins
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Department Of Defense
  • Elements
  • Gene Expression
  • Genes
  • Genetics
  • Inhibitors
  • Lung Cancer
  • Maryland
  • Mass Spectrometry
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Proteins
  • Small Molecules
  • Statistics
  • Targeting
  • Universities
  • Xenografts

Fields of Study

  • Medicine

Readers

  • Oncology (Cancer Research).